Metabolomics of transformed MDA-MB-231 cell lines expressing different levels of human arylamine N-acetyltransferase 1 (NAT1). by Carlisle, Samantha Marie
University of Louisville
ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
8-2015
Metabolomics of transformed MDA-MB-231 cell




Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Master's Thesis is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted
for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository.
This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.
Recommended Citation
Carlisle, Samantha Marie, "Metabolomics of transformed MDA-MB-231 cell lines expressing different levels of human arylamine N-
acetyltransferase 1 (NAT1)." (2015). Electronic Theses and Dissertations. Paper 2218.
https://doi.org/10.18297/etd/2218
METABOLOMICS OF TRANSFORMED MDA-MB-231 CELL LINES EXPRESSING DIFFERENT 










Samantha Marie Carlisle 








Submitted to the Faculty of the 
School of Medicine of the University of Louisville 
in Partial Fulfillment of the Requirements 









Master of Science 
 






Department of Pharmacology and Toxicology 









Copyright 2015 by Samantha Marie Carlisle 
 
 
All rights reserved 
 
	   ii 
METABOLOMICS OF TRANSFORMED MDA-MB-231 CELL LINES EXPRESSING DIFFERENT 




Samantha Marie Carlisle 
B.S., University of Louisville, 2012 
 
 















      
David W. Hein, Ph.D. 
 
      
J. Christopher States, Ph.D. 
 
      
Xiang Zhang, Ph.D. 
 
      
Carolyn M. Klinge, Ph.D. 
 
      
Shesh N. Rai, Ph.D. 
  
	   iii 
ACKNOWLEDGEMENTS 
 
 I would first and foremost like to thank my mentor, Dr. David Hein, for all of his advice 
and direction over the past three years. I would also like to thank my committee members, Dr. J. 
Christopher States, Dr. Xiang Zhang, Dr. Carolyn Klinge, and Dr. Shesh Rai, for all of their 
feedback and helpful suggestions throughout this process. Lastly, I would like to acknowledge 
and thank all of my friends and family who have provided unwavering encouragement and 





	   iv 
ABSTRACT
 
METABOLOMICS OF TRANSFORMED MDA-MB-231 CELL LINES EXPRESSING DIFFERENT 
LEVELS OF HUMAN ARYLAMINE N-ACETYLTRANSFERASE 1 (NAT1) 
 
 
Samantha Marie Carlisle 
 
July 9, 2015 
 
 
 Human arylamine N-acetyltransferase 1 (NAT1) is a phase II xenobiotic metabolizing 
enzyme that is found in almost all tissues of the body. Expression of NAT1 is commonly elevated 
in several cancers including breast cancer. However, the exact mechanism by which NAT1 
expression affects cancer risk and progression remains unclear. Three MDA-MB-231 breast 
adenocarcinoma cell lines that stably express wild-type, increased, and decreased levels of 
human NAT1 have been constructed and characterized for NAT1 mRNA, NAT1 acetylation 
activity, cell doubling rates, and endogenous acetyl-CoA levels. Differences in polar metabolic 
profile between these three cell lines were investigated using a comprehensive GC×GC−TOF MS 
system. Increased levels of human NAT1 in the transformed cell lines resulted in a statistically 
significant decreased abundance of the metabolite palmitoleic acid with one-way ANOVA p = 
0.0004, when compared to normal and decreased levels of human NAT1. We hypothesize that 
increased NAT1 activity leads to increased hydrolysis of acetyl-CoA thus leaving less acetyl-CoA 
available to participate in other reactions. The fatty acid synthesis pathway utilizes acetyl-CoA in 
the first two reactions of the pathway and eventually leads to the synthesis of palmitoleic acid 
(16:1). These data suggest a link between increased levels of NAT1 activity and decreased flux of 
acetyl-CoA through this portion of the fatty acid synthesis pathway. 
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INTRODUCTION
 
 It is estimated that in 2015 breast cancer will account for 29% of all new cancer cases 
diagnosed in women and 15% of all cancer related deaths in women [1]. From 2002-2003 there 
was a sharp decline in breast cancer incidence in non-Hispanic Caucasian women correlating 
with the decreased use of hormone replacement therapy, but that trend did not continue into the 
subsequent years [2]. From 2004 to 2010, breast cancer incidence rates have not significantly 
changed, thus emphasizing the necessity of further investigation into what factors are affecting 
breast cancer risk and progression. As more is known about breast cancer, preventative and 
treatment options can be improved. 
 Current breast cancer treatment options include surgery, sentinel lymph node biopsy 
followed by surgery, radiation therapy, hormone therapy, targeted therapy, and chemotherapy [3]. 
Also, for people with a history of familial breast cancer, genetic screenings for mutations in the 
tumor suppressor genes BRCA1 and BRCA2 serve as a way to identify breast cancer risk. 
Potential onset of the disease can be prevented if mastectomies are performed on those who test 
positive for mutations in those genes. Although there are many treatment options for breast 
cancer, all come with complicated physical and emotional side effects that decrease the quality of 
life of patients. Unfortunately, these treatment and preventative options are not always 100% 
effective at eliminating all the cancerous cells, leaving the risk of relapse in addition to the harmful 
side effects. Also some cancers, during the course of treatment, become resistant to radiation 
therapy, hormone therapy, targeted therapy, and chemotherapy meaning additional measures 
must be taken. Due to the harmful side effects, restricted effectiveness, and risk for relapse 
associated with current therapies it is important that new treatment options and targets are 
explored and elucidated. 
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Early detection of breast cancer is extremely important. When breast cancer is detected 
in the localized stage, the five-year relative survival rate is an incredible 99%, but when detected 
in the distant stage, the five-year relative survival rate is a disappointing 24% [1]. In the earliest 
stages of breast cancer, the cancerous cells are localized at the point of origin and can be 
removed by surgery with no further intervention required. As breast cancer progresses, more 
mutations are incurred and this frequently leads to the breast cancer becoming more aggressive, 
invasive, and harder to treat. Once breast cancer has undergone metastasis, harsher and more 
aggressive treatments are required. A better understanding of what influences disease risk and 
drives disease progression is needed to increase detection of breast cancer in the earliest stage 
when it is the most treatable. 
Breast cancer is a heterogeneous disease that can be subclassified according to multiple 
classifiers including pathology, tumor grade and stage, gene and protein expression, and 
immunohistochemical characteristics. One of the most commonly used methods to classify breast 
cancer is immunohistochemically according to estrogen receptor (ER), progesterone receptor 
(PR), and HER2/neu status. Using this classification system, a triple negative breast cancer 
would not express any of these receptors while a triple positive breast cancer would express all 
three receptors. Recently, classification based on gene and protein expression has become of 
more interest because it may provide clues about what treatment options will be the most 
effective for each specific cancer case. Sorlie et al. conducted a study in which gene expression 
data of 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas, and four 
normal breast tissues were evaluated [4]. Based on analysis by hierarchical clustering, six 
subtypes were defined. These breast cancer subtypes are 1. Luminal Subtype A, 2. Luminal 
Subtype B, 3. Luminal Subtype C, 4. Basal-like, 5. ERBB2+, and 6. Normal Breast-like; these 
subtypes are associated with different clinical outcomes in addition to the differences in gene and 
protein expression. Other studies have since been conducted looking at the prevalence of each of 
these subtypes and have investigated further differences between them [5]. 
Human arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) are cytosolic phase II 
xenobiotic metabolizing isozymes that acetylate a wide range of aromatic and heterocyclic 
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amines via a ping-pong bi-bi reaction mechanism [6],[7]. NAT1 and NAT2 genes are both located 
on chromosome 8p22 [8]. Although NAT1 and NAT2 share approximately 87% coding sequence 
homology [9] functional studies have demonstrated significant differences between the two 
isozymes in terms of substrate specificity and tissue localization. NAT1 shows substrate 
specificity for p-aminosalicylate and p-aminobenzoic acid (PABA) while NAT2 shows substrate 
specificity for isoniazid, sulfamethazine, and procainamide [10]. These distinct but overlapping 
substrate specificities have been shown to be due to differences in the substrate binding site of 
the enzymes [11]. NAT1 and NAT2 also vary in terms of tissue expression with NAT1 being 
expressed in most body tissues but NAT2 expression is limited primarily to the liver and GI tract 
tissues. Although NAT1 has been shown to be expressed in most body tissues, the only known 
endogenous substrate of NAT1, to date, is p-aminobenzoyl-glutamate (PABA-glu), a folate 
catabolite [12]. We suspect NAT1 has other endogenous substrates that have yet to be 
elucidated, given the extensive tissue distribution and presence in almost all species. 
Humans are frequently exposed to NAT substrates. Many therapeutic drugs, including 
arylamine drugs such as procainamide, dapsone, and aminoglutethimide, hydrazine drugs such 
as isoniazid, hydralazine and phenelzine, and secondary arylamine and hydrazine metabolites 
such as sulfasalazine, clonazepam, acebutolol, and caffeine are metabolized by NAT [13]. 
Aromatic amines, another class of NAT substrates, are found as the byproducts of the 
manufacturing of compounds such as polyurethane foams, dyes, pesticides, pharmaceuticals, 
and semi-conductors [14]. Aromatic amines are also found in environmental pollution such as 
diesel exhaust, combustion of wood chips and rubber, tobacco smoke and well-done grilled 
meats [15]. Several of these NAT substrates are environmental carcinogens and their acetylation 
leads to either deactivation or bioactivation. One of the most well known and studied NAT 
substrates is 4-aminobiphenyl (ABP), a carcinogenic aromatic amine that is a major constituent of 
cigarette smoke [16]. The NAT’s play a major role in the deactivation and bioactivation of 
carcinogenic aromatic amines and arylamines. Carcinogenic NAT substrates, such as ABP, can 
either be N-acetylated (usually deactivation) by NAT, or if first acted upon by a cytochrome P450 
enzyme, they can be O-acetylated (usually bioactivation) by NAT. Once bioactivated, these 
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compounds can spontaneously form arylnitrenium ions leading to DNA adducts. If not repaired by 
nucleotide excision repair (NER), these DNA adducts can lead to mutagenesis and possible 
cancer initiation. 
Recently it has been shown that human NAT1 can also catalyze the direct hydrolysis of 
acetyl-CoA in the absence of a NAT1 arylamine substrate using folate as a cofactor [17]. In this 
reaction, the folate is not acetylated, instead the acetate released forms acetyl-CoA is excreted 
into the surrounding bulk solvent. Interestingly, the same reaction was not detected in the 
presence of human NAT2 instead of human NAT1. The discovery of this additional function of 
NAT1 provides support for the hypothesis that NAT1 has an undetermined endogenous role in 
addition to the role NAT1 serves as a phase II xenobiotic metabolizing enzyme.  
Historically, NAT2 has been of more interest because of the role single nucleotide 
polymorphisms (SNPs) in NAT2 play in the metabolism of isoniazid, an anti-tuberculosis drug. 
Decreased NAT2 activity due to the presence of SNP’s in “slow” acetylators increases the risk of 
developing hepatotoxicity during treatment because isoniazid is eliminated slower when 
compared to “rapid” acetylators and accumulates in the liver [18-20]. NAT1 has recently become 
of more interest because of the possible link between NAT1 expression and cancer risk and 
progression. Examination of publicly available microarray data by others, has shown that changes 
in the levels of NAT1 mRNA are associated with specific cancers and cancer subtypes [21]. Of all 
cancers, the association between NAT1 and breast cancer has been the most extensively 
investigated. A microarray study of 66 breast cancer samples in 2009 by Casey et al., revealed 
NAT1 expression was higher in invasive carcinoma compared with normal tissue [21, 22]. Also, 
Yuan et al. showed that NAT1 is commonly amplified in breast carcinomas using computational 
approaches and a previously published microarray dataset containing 89 breast cancer samples 
[23, 24]. Adam et al. have shown by comparative proteomic analysis of 8 normal breast samples 
and 25 breast cancer derived tissues that NAT1 is elevated in invasive ductal carcinoma (IDC) 
and invasive lobular carcinoma (ILC) when compared to the normal tissue [25]. In the same study 
it was also shown that overexpression of NAT1 in HB4a, conditionally immortalized human 
mammary luminal epithelial derived cells, enhanced cell growth and resistance to etoposide, a 
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cytotoxic anticancer drug, relative to control cells [25]. Smid et al showed in a study of 107 breast 
cancer samples that high NAT1 levels in primary tumors were significantly associated with 
increased metastasis to the bone [26].  
Initially, NAT1 was thought to be monomorphic in terms of acetylation activity but 
additional studies have since revealed NAT1 is subject to separate polymorphisms from NAT2 
[27-29]. NAT1 contains SNP’s located in the protein region and in the 3’-untranslated regions of 
the gene that affect the level of enzymatic activity. Although SNP’s in NAT1 are less common 
than those found in NAT2 they still confer distinct differences in NAT1 activity in the human 
population. To date, there have been 28 NAT1 alleles identified. Due to the infrequency at which 
they occur, roughly half of the NAT1 alleles have yet to be phenotypically defined as conferring 
normal, elevated, or decreased NAT1 activity. Data regarding human NAT1 alleles have been 
collected and presented at http://nat.mbg.duth.gr/Human%20NAT1%20alleles_2013.htm [30]. 
The NAT1*4 allele is defined as the reference allele. NAT1*14A, NAT1*14B, NAT1*17, and 
NAT1*22 have all been defined as having activity lower than NAT1*4. NAT1*15, NAT1*19A, and 
NAT1*19B have been defined as coding for a truncated protein that has no activity. NAT1*20, 
NAT1*21, NAT1*23, NAT1*24, NAT1*25, and NAT1*27 have all been defined as having activity 
equivalent to the reference allele, NAT1*4. There have been conflicting reports about the activity 
of the NAT1*10 allele, some report increased NAT1 activity when compared to the reference 
allele but others have seen no difference [31-33]. Interestingly, in a study by Wakefield et al. that 
reported the NAT1 activity and genotypes of multiple breast cancer cell lines, the cell lines ZR-75-
1 and MDA-MB-231 had the same NAT1 genotype (NAT1*4/NAT1*4) but varied in activity by 
greater than 1,000 fold [34]. In the ZR-75-1 cell line, elevated levels of NAT1 were not due to 
alterations in gene copy number. Further analysis has indicated that the NAT1 transcripts in the 
ZR-75-1 cell line are produced from the distal promoter NATa while the NAT1 transcripts 
produced in all the other cell lines tested were derived from the NATb promoter [35]. There have 
also been conflicting data regarding the extent to which these polymorphisms in NAT1 modify risk 
of developing breast, colorectal, urinary bladder, head and neck, lung, and prostate cancers. 
Adding to the confusion, NAT1 activity is also modulated by a plethora of post-translational and 
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environmental factors, including direct chemical modification of the active-site cysteine by 
reactive chemical species [36, 37], factors that induce oxidative stress and alter GSH levels [21], 
cytokines [38], and through inhibition by small molecule inhibitors [39-41], heavy metals [42], 
plant extracts [37], nanoparticles [43], and therapeutic agents [44]. The NAT1 gene copy number 
can also be increased or decreased when compared to the standard of two, thus causing 
differences in NAT1 activity. 
Several studies have demonstrated that expression of NAT1 is significantly linked to 
estrogen receptor status in breast cancer samples [45-47]. An evaluation of previously published 
microarray data that compared gene expression between ER-positive and ER-negative tissues by 
Wakefield et al. showed that NAT1 is in the top three most overexpressed genes in ER-positive 
tissue in over 50% of the studies [34]. ER-positive breast cancer can further be subclassified as 
luminal A (classically defined as ERhigh Ki67low) and luminal B (classically defined as ERlow 
Ki67high). In a recent study investigating differences in the luminal A and luminal B subtypes of 
ER-positive breast cancer published by Endo et al., it was shown that the microRNA (miRNA), 
miR-1290 is downregulated in luminal A tumors when compared to luminal B tumors [48]. The 
same group has shown in a later publication that miR-1290 binds to a site in the NAT1 3’-UTR 
and NAT1 is directly downregulated in a dose-dependent manner by miR-1290 [49]. These data 
suggests that downregulation of miR-1290 in luminal A breast cancer leads to overexpression of 
NAT1. Interestingly, overexpression of NAT1 in ER-positive breast cancer has been shown to be 
correlated with a decreased 5-year relapse rate [50] and NAT1 expression has been shown to be 
negatively correlated with tumor size [48]. 
There have been multiple studies investigating the effects the inhibition of NAT1 has on 
immortalized cancer cells. In one study by Tiang et al., in which NAT1 activity in HT-29 cells, 
immortalized human colorectal adenocarcinoma cells, was decreased through the use of shRNA, 
significant changes in cell growth and morphology were observed when cells were at high density 
as opposed to sub-confluent density [51]. In the same study it was also shown that NAT1 
knockdown led to increased E-cadherin protein expression and impeded anchorage-independent 
growth [51]. Studies have also been conducted in which NAT1 was inhibited by small molecules. 
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In one such study Rhod-o-hp, a rhodanine derivative, was used to decrease NAT1 activity in 
MDA-MB-231 cells, breast adenocarcinoma cells. This study revealed that Rhod-o-hp inhibits 
anchorage independent growth and invasiveness of MDA-MD-231 cells, which was comparable 
to the effects seen with knockdown of NAT1 via shRNA, suggesting Rhod-o-hp’s effect on MDA-
MB-231 cells are caused by inhibition of NAT1 [40]. We have seen similar results in our lab with 
the NAT1 specific small molecule inhibitor 9,10-dihydro-9,10-dioxo-1,2-anthracenediyl diethyl 
ester (DDADE) [41]. DDADE was identified through an in silco screening of over 700,000 small 
molecules in the ZINC (a free database of commercially-available compounds for virtual 
screening) library using the crystal structure of human NAT1 to predict binding affinity. Studies in 
our lab have shown that DDADE decreases NAT1 catalyzed N-acetylation and O-acetylation of 
arylamine substrates in human breast adenocarcinoma cells. DDADE has also been shown to 
decrease cell adhesion and cell invasion in human breast cancer cells. 
Cancer cells characteristically exhibit rapid, uncontrolled growth therefore requiring 
increased levels of energy and cellular components when compared to normal cells. 
Reprogramming of cellular metabolism to meet these needs is one of the next generation 
hallmarks of cancer proposed by Hanahan and Weinberg [52]. Although, the exact mechanism by 
which cellular metabolism is reprogrammed remains unclear, it is likely specific to each type of 
cancer and is also influenced by a combination of factors. Metabolomics studies are able to 
generate insights into which pathways have been modified, by measuring the abundance of 
metabolites and then comparing the abundances between groups with defined differences.  
Historically, studies investigating the role NAT1 plays in cancer risk and progression have 
focused on NAT1’s role as a xenobiotic metabolizing enzyme that can transform carcinogens, but 
we propose NAT1 affects cancer risk and progression through regulation of acetyl-CoA levels in 
the human body. It is our hypothesis that changing the level of NAT1 activity will lead to 
alterations in the levels of acetyl-CoA. Increased NAT1 activity would lead to increased hydrolysis 
of acetyl-CoA therefore less acetyl-CoA would be available. Conversely, decreased NAT1 activity 
would lead to decreased hydrolysis of acetyl-CoA therefore more free acetyl-CoA would be 
available. Preceding this study, metabolomics had not been utilized to investigate how differences 
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in NAT1 activity alter the abundance distribution of metabolites in breast cancer cells. It is 
expected that if NAT1 activity is involved in cancer risk or progression a change in metabolite 
abundance distribution could be observed between breast cancer cell lines representing varying 
levels of NAT1 activity. These potential changes are important to elucidate because 
understanding how varying levels of NAT1 affect metabolite abundances can give us a better 
understanding of which cellular pathways are altered as a result of varying levels of NAT1 activity. 
An improved understanding of cellular reprogramming as a result of NAT1 activity could lead to 
earlier cancer detection and more effective treatment options. 
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MATERIALS AND METHODS
 
CONSTRUCTION OF THE THREE STABLY TRANSFECTED MDA-MB-231 CELL LINES 
 The breast adenocarcinoma cell line, MDA-MB-231, was purchased from ATCC 
(Manassas, VA) and cultured in high-glucose Dulbecco's Modified Eagle Medium (DMEM), with 
10% fetal bovine serum, 5% glutamine, and 5% penicillin/streptomycin added. The Flp-In™ 
System (Life Technologies, Grand Island, NY) was used previously in our lab (by Mark Doll) to 
create a single Flp Recombination Target (FRT) site in the parent MDA-MB-231 cell line 
according to manufacturer’s instructions. SureSilencing™ NAT1 specific shRNA plasmids and a 
corresponding scrambled shRNA plasmid were purchased from SA Biosciences (Valencia, CA). It 
has previously been shown that the SureSilencing™ NAT1 shRNA Clone 3 is the most effective 
of the four provided by SA Biosciences at silencing NAT1 activity in the MDA-MB-231 cell line, 
therefore Clone 3 was chosen as the shRNA plasmid that would be used when generating a 
stable NAT1 knockdown MDA-MB-231 cell line. Next, the shRNA plasmids containing the 
scrambled and NAT1 clone 3 shRNA sequences were integrated into the pcDNA5/FRT vector 
from the pGeneclip™ vector, independently. For the construction of the MDA-MB-231 cell line 
overexpressing NAT1, the NATb/NAT1*4 plasmid in the pcDNA5/FRT vector previously 
constructed in our lab [53] was chosen. The construction of a MDA-MB-231 cell line containing a 
single FRT site in the transcriptionally active region allowed us to transfect each of the plasmids 
into the same genetic location in different cells, thus creating three new MDA-MB-231 cell lines 
whose only difference is the level of NAT1 activity. The pcDNA5/FRT plasmids containing the 
scrambled shRNA, NAT1 clone 3 shRNA plasmid or NATb/NAT1*4 overexpression plasmid, were 
co-transfected into the MDA-MB-231 cell line containing the single FRT site with pOG44 (Life 
Technologies), a Flp recombinase expression plasmid, using Amaxa Cell Line Nucleofector Kit V 
(Lonza, Basel, Switzerland) following manufacturer’s instructions. Resulting cells were then 
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cultured in complete DMEM media containing 500 µg/mL hygromycin to select for cells that had 
successfully undergone transfection and stably integrated the pcDNA5/FRT plasmid into their 
genomic DNA since the pcDNA5/FRT vector contains a hygromycin resistance cassette. 
Hygromycin resistant colonies were selected approximately two weeks after transfection and 
isolated using cloning cylinders. The resulting transformed cell lines, “Scrambled”, “Down”, and 
“Up”, express parental, decreased, and increased NAT1 activity, respectively (Figure 1). 
CHARACTERIZATION OF SAMPLES 
 Total RNA was isolated from each transformed cell line using the RNeasy Mini Kit 
(Qiagen, Germantown, MD) per manufacturer’s instructions. The High Capacity Reverse 
Transcriptase kit (Life Technologies, Grand Island, NY) was then used to synthesize cDNA 
according to manufacturer’s instructions. NAT1 mRNA was quantitated for each transformed cell 
line in triplicate using quantitative real-time polymerase chain reaction (qRT-PCR) and NAT1 
specific primers and probes (Life Technologies, Grand Island, NY). The PCR conditions 
suggested by the manufacturer were used.  
NAT1 N-acetylation activity was measured for each transformed cell line in triplicate via 
high pressure liquid chromatography (HPLC) in the presence of the NAT1 specific substrate p-
aminobenzoic acid (PABA) by measuring the appearance of acetylated product. Cells from each 
transformed cell line were collected using a cell-scraper to detach the cells from the plate and 
then the cells were rinsed with 1 X PBS. Cells were then lysed in 20 mM sodium phosphate, 1 
mM EDTA, 0.2% Triton X-100 (pH 7.4) with the addition of 1 mM DTT, 100 µM PMSF, 1 µg/ml 
Aprotinin, and 2 µM pepstatin A. Cell lysate was centrifuged at 15,000 x g for 10 min and the 
supernatant saved for subsequent NAT1 activity assays. The resulting cell lysates were 
incubated with 10 µM para-aminobenzoic acid (PABA) and 100 µM acetyl-CoA at 37°C for 10 
minutes. The reaction was stopped by the addition of 1 M acetic acid at a volume equal to 1/10 of 
the total reaction volume. Samples were then centrifuged at 10,000 x g for 10 minutes and the 
resulting supernatant was collected for analysis of N-acetyl-PABA levels via HPLC.  
To determine a cell doubling rate each transformed cell line was plated at an initial 
density of 25,000 cells per well in 12 well plates and then counted on a cell counter daily for 5  





Figure 1: Construction of MDA-MB-231 Breast Cancer Cells That Express Varying Levels 
of NAT1 Activity  
The Flp-In™ System (Life Technologies, Grand Island, NY) was used to insert a single FRT site 
into the parent MDA-MB-231 cell line. The MDA-MB-231 cell line containing the FRT site was 
then stably transfected with either with a plasmid containing a nonspecific shRNA plasmid into the 
FRT site (Scrambled), a plasmid containing NAT1 specific shRNA into the FRT site (Down), or a 
plasmid containing the NATb/NAT1*4 vector into the FRT site (Up). Each plasmid contained a 
hygromycin resistant cassette therefore cells that had successfully been stably transfected were 
then selected for using hygromycin  
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days. Cells were plated on day 1 and allowed to adjust for 24 hours before counting on day 2. 
Data were plotted to ensure cells were in the logarithmic growth phase. A cell doubling rate was 
calculated for each day using Equation 1 (shown below) and then rates were averaged over the 5 
day time period to get a final cell doubling rate.  
Equation 1: 𝐶𝑒𝑙𝑙  𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔  𝑅𝑎𝑡𝑒 = 1/(((log 𝑏 − log  (𝑎))×3.32)/(𝑡! − 𝑡!)) 
In the equation, 𝑏 = cell number on day n, 𝑎 = cell number on day n-1, 𝑡! = hours passed since 
plating when cells were counted on day n, and 𝑡! = hours passed since plating when cells were 
counted on day n-1. 
 Endogenous acetyl-CoA levels of the three transformed MDA-MB-231 cell lines were 
measured in triplicate via HPLC-UV. Cells were cultured in high-glucose Dulbecco's Modified 
Eagle Medium (DMEM), with 10% fetal bovine serum, 5% glutamine, and 5% 
penicillin/streptomycin added in 35 mm plates to approximately 80% confluence. Medium was 
then aspirated from each plate followed by a rinse with 10 mL of 1 X PBS. After removal of the 
PBS, cells were released from the plate with the addition of 0.5 mL trypsin per plate and then 
resuspended in 5 mL of 20% medium and 80% PBS. Cells were then counted via a Coulter 
automated cell counter. Cell suspensions were then centrifuged in 15 mL tubes for 2.5 minutes at 
400 X g at 4°C. Supernatant was removed and cell pellets were resuspended in 1 mL of cold 
PBS. Cell suspensions were centrifuged again in 15 mL tubes for 2.5 minutes at 400 X g at 4°C. 
Cells were transferred to cooled 1.5 mL eppendorf tubes by resuspending them in 1 mL of cold 
PBS. Resulting cell suspensions were then centrifuged in the cold room at 300 X g for 
approximately 5 minutes. Supernatant was removed and cells were lysed in 100 µL of 5% 5-
sulfosalicylic acid by pipetting up and down. The resulting suspension was centrifuged in the cold 
room at 15,000 X g for approximately 10 minutes. Supernatant (100 µL) was collected and 
injected onto a C18 reverse-phase HPLC column (250 mm × 4 mm; 5 µM pore size). Reactants 
and products were separated and quantitated using a Beckman System Gold high performance 
liquid chromatography (HPLC) system. HPLC separation of CoA and acetyl-CoA was achieved 
using a linear gradient of 100:0 sodium phosphate (NaH2PO4) pH 4: methanol to 0:100 sodium 
phosphate pH 4: methanol over 20 minutes and was quantitated by absorbance at 260 nm.  
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Since the cells were lysed in 5% 5-sulfosalicylic acid, this buffer solution was used as a reference 
to subtract any background acetyl-CoA coming from the lysis buffer. 
METABOLOMICS 
Each sample of cells for metabolomic analyses contained approximately five million cells 
with a wet weight of 20 mg. The cells were lysed by homogenization in 200 µL of deionized water. 
Next, samples were mixed using a vortex mixer for two minutes after the addition of 800 µL of ice 
cold methanol. Samples were then stored on ice for ten minutes followed by three more minutes 
of mixing on the vortex mixer. Next, samples were centrifuged at 12,000 X g for ten minutes. 
Supernatant (800 µL) was then transferred to a 1.5 mL eppendorf tube and dried via speed 
vacuum until dry (roughly three hours). Cell pellets used for metabolomics samples were frozen 
at -80°C until day of lysis and extraction. 
Polar metabolites were extracted from cell pellet samples of each transformed cell line in 
octuplicate using a mixture of 80% methanol and 20% water. Samples were then derivitized with 
N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) followed by GC×GC−TOF MS to 
identify metabolites. The GC×GC−TOF MS data were then processed using LECO’s instrument 
control software ChromaTOF for peak picking and tentative metabolite identification, followed by 
retention index matching, peak merging and peak list alignment (Figure 2). Based on the results 
of our analyses (described in Statistical Analysis), a list of metabolites were subject to technical 
validation i.e., analysis of standards for the given metabolites on GC×GC−TOF MS and 
comparison of those results to the experimental data to provide further evidence of correct 
metabolite identification. 
STATISTICAL ANALYSIS 
One-way ANOVA was conducted on the data collected during characterization of the 
transformed cell lines; Post-hoc t-tests were conducted when the one-way ANOVA statistic was 
significant. The analyses were performed using Prism® software (GraphPad software, La Jolla, 
CA). Two approaches were used to analyze the metabolomics data obtained, 1. univariate and 2. 
multivariate/multivariable analyses (Figure 3). Imputation, normalization, and statistical 
significance tests, including student’s t-tests and one-way ANOVA were performed using R 





Figure 2: Metabolomics Experimental Design  
In this figure, Scrambled refers to the MDA-MB-231 cell line that was stably transfected with a 
plasmid containing a nonspecific shRNA plasmid into the FRT site, Down refers to the MDA-MB-
231 cell line that was stably transfected with a plasmid containing NAT1 specific shRNA into the 
FRT site, and Up refers to the MDA-MB-231 cell line that was stably transfected with a plasmid 
containing the NATb/NAT1*4 vector into the FRT site. Cells from eight biological replicates of 
each cell line were first harvest, counted, and lysed. Next polar metabolites were isolated, 
followed by derivitization with MTBSTFA. The resulting samples were then analyzed by two-
dimensional gas chromatography time-of-flight mass spectrometry. 





Figure 3: Metabolomics Data Analyses Workflow  
In this figure, the workflow for the analyses of the data collected from the two-dimensional gas 
chromatography time-of-flight mass spectrometer is shown. 
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software (R Core Team (2015), Vienna, Austria). Q-values for the one-way ANOVA and t-test 
comparisons were computed from the raw p-values, respectively, using the R package qvalue 
(John Storey, R package version 2.0.0.). To better visualize the data, volcano plots and box plots 
were created using R software. Metabolite abundance fold-change between the Scrambled & Up, 
Scrambled & Down, and Down & Up groups were calculated using Equation 2 (shown below). 
Equation 2: 𝐹𝐶 = 2 !"#!!!  
In the equation, 𝐹𝐶 = fold-change, 𝐴= average metabolite abundance in the reference group, 𝐵= 
average metabolite abundance in the comparison group.  A negative sign was added to the fold-
change when metabolite abundance was lower in the comparison group compared to the 
reference group. The volcano plots plot the log base 2 of the fold change between the two 
specific groups versus the negative log base 10 of the unadjusted student’s t-test p-value 
between the two specific groups. The box plots plot the median normalized abundance levels for 
each metabolite. Then, Principal Component Analysis (PCA), Partial Least Squares Discriminate 
Analysis (PLS-DA), and Orthogonal Partial Least Squares Discriminate Analysis (OPLS-DA) were 
conducted to give a more complete picture of metabolite interactions. The loadings of Component 
1 from the OPLS-DA results were plotted to visualize which metabolites were contributing the 
most to the separation of the groups. 
PATHWAY ANALYSIS 
 Pathway analysis was conducted on only those metabolites that were verified and found 
to be significant following student’s t-tests and/or one-way ANOVA. We began the pathway 
analysis portion of this study by first locating acetyl-CoA on the Roche Biochemical Pathways 
Chart (F. Hoffmann-La Roche AG, Basel, Switzerland) and then following all possible pathways to 
and from acetyl-CoA to locate the metabolites that were verified and significant. Some 
metabolites were not located in a pathway involving acetyl-CoA therefore they have not been 
considered further at this time. For those that were located in a pathway involving acetyl-CoA, we 
then developed hypotheses that could explain how each metabolite’s abundance distribution 
across the three groups related to the amount of free acetyl-CoA available.
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RESULTS
 
CHARACTERIZATION OF SAMPLES 
Three stably transfected MDA-MB-231 cell lines, Scrambled, Up, and Down, expressing 
parental, increased, and decreased levels of NAT1 activity, respectively, have been constructed. 
The three cell lines were characterized to confirm we had successfully constructed stable cell 
lines that express parental, increased, and decreased NAT1 activity relative to the parent MDA-
MB-231 cell line. First, the levels of NAT1 mRNA were measured via quantitative real-time PCR 
with NAT1 specific primers and probes. Differences in NAT1 mRNA expression of the Parent, 
Scrambled, Down, and Up cell lines were tested by one-way ANOVA (p<0.0001) and found to be 
statistically significant (Figure 4). The NAT1 mRNA of the parent MDA-MB-231 cell line that 
contains the FRT site but was not transfected with shRNA plasmids was measured and found to 
express 90% of the NAT1 mRNA that the Scrambled cell line does. This difference in NAT1 
mRNA between the Parent and Scrambled cell lines was not statistically significant (p>0.05) 
when tested further by a Tukey’s post-hoc test. Relative to the Scrambled cell line, the Down cell 
line expressed 50% of the NAT1 mRNA and the Up cell line expressed 3100% of the NAT1 
mRNA. Following a Tukey’s post-hoc test NAT1 mRNA expression was significantly different 
between the Scrambled & Up (p ≤ 0.001) and Down & Up (p ≤ 0.001) cell lines but not between 
the Scrambled & Down cell lines (p>0.05).  
Next, the levels of NAT1 activity were measured via detection of acetylated product by 
HPLC using the NAT1 specific substrate PABA. Differences in NAT1 PABA acetylation activity of 
the Parent, Scrambled, Down, and Up cell lines were tested by one-way ANOVA (p<0.0001) and 
found to be statistically significant (Figure 5). The parent MDA-MB-231 cell line, that contains only 
the FRT site, was found to have a NAT1 activity of 19.2 ± 1.2 nmol PABA acetylated/min/mg 
protein. The Scrambled cell line, that contains the FRT site and was transfected with the NAT1 





Figure 4: NAT1 mRNA expression of MDA-MB-231 transformed cell lines.  
In this figure, Scrambled refers to the MDA-MB-231 cell line that was stably transfected with a 
plasmid containing a nonspecific shRNA plasmid into the FRT site, Down refers to the MDA-MB-
231 cell line that was stably transfected with a plasmid containing NAT1 specific shRNA into the 
FRT site, and Up refers to the MDA-MB-231 cell line that was stably transfected with a plasmid 
containing the NATb/NAT1*4 vector into the FRT site. Relative NAT1 mRNA levels in cell lines 
normalized to scrambled shRNA cell line. Bars represent results from three separate 
determinations with mean ± SD. Statistical significance was determined using one-way ANOVA 








































Figure 5: NAT1 PABA acetylation activity of MDA-MB-231 transformed cell lines.  
PABA N-acetyltransferase activity of transformed cell line lysates were measured via HPLC. In 
this figure, Scrambled refers to the MDA-MB-231 cell line that was stably transfected with a 
plasmid containing a nonspecific shRNA plasmid into the FRT site, Down refers to the MDA-MB-
231 cell line that was stably transfected with a plasmid containing NAT1 specific shRNA into the 
FRT site, and Up refers to the MDA-MB-231 cell line that was stably transfected with a plasmid 
containing the NATb/NAT1*4 vector into the FRT site. Bars represent results from three separate 
determinations with mean ± SD. Statistical significance was determined using one-way ANOVA 
(p<0.0001) followed by a Tukey’s post-hoc test. NS = not significant, *= ≤ 0.05, 
*** = p ≤ 0.001. 
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scrambled shRNA, was found to have a NAT1 activity of 18.9 ± 0.2 nmol PABA 
acetylated/min/mg protein. The Up cell line, that contains the FRT site and was transfected with 
the NATb/NAT1*4 overexpression plasmid, was found to have a NAT1 activity of 233.9 ± 2.2 
nmol PABA acetylated/min/mg protein. Finally, the Down cell line, that does contain the FRT site 
and was transfected with the NAT1 clone 3 shRNA, was found to have a NAT1 activity of 11.6 ± 
0.6 nmol PABA acetylated/min/mg protein. When compared to the Scrambled cell line, the Down 
cell line had 61% of the NAT1 activity and the Up cell line had 1240% of the NAT1 activity. 
Following a Tukey’s post-hoc test the NAT1 activity of the parent MDA-MB-231 cell line that 
contains the FRT site but was not transfected with shRNA plasmids did not significantly vary 
(p>0.05) in activity from the NAT1 activity of the Scrambled cell line. Further analysis does not 
include the parent MDA-MB-231 cell line since there was no statistically significant difference 
between its levels of NAT1 mRNA & NAT1 activity and that of the Scrambled cell line.  
Next, the doubling times of the three cell lines were measured by counting the cells over 
a period of 6 days. The doubling rate of the Scrambled, Up, and Down cell lines were calculated 
to be 27.4 ± 0.3 hours, 23.9 ± 1.2 hours, and 27.2 ± 2.4 hours, respectively. Following a one-way 
ANOVA (p=0.3850) the doubling rates of the three transformed cell lines were not found to be 
significantly different (Figure 6). Finally, endogenous acetyl-CoA levels were measured via HPLC-
UV. Differences in endogenous acetyl-CoA levels were tested by one-way ANOVA (p=0.0218) 
and found to be statistically significant (Figure 7). The acetyl-CoA levels of the Scrambled, Up, 
and Down transformed cell lines were found to be 0.046 ± 0.0025 nmoles acetyl-CoA/1,000,000 
cells, 0.031 ± 0.0026 nmoles acetyl-CoA/1,000,000 cells, and 0.049 ± 0.0072 nmoles acetyl-
CoA/1,000,000 cells, respectively. Tukey’s post-hoc test showed that only the difference in 
endogenous acetyl-CoA levels between the Down and Up group was statistically significant (p < 
0.05). 
METABOLOMICS 
All metabolites were given a metabolite number (arbitrarily) to provide a unique 
identification since some metabolites appeared multiple times and others were unnamed. Of all  
  





Figure 6: Doubling Time of MDA-MB-231 transformed cell lines. 
Determination of doubling time in the transformed cell lines. In this figure, Scrambled refers to the 
MDA-MB-231 cell line that has parental levels of NAT1 activity, Down refers to the MDA-MB-231 
cell line that has decreased NAT1 activity, and Up refers to the MDA-MB-231 cell line that has 
increased NAT1 activity. Bars represent results from three separate determinations with mean ± 
SD. Statistical significance was tested by one-way ANOVA (p=0.3850).
Doubling Time of Transformed MDA-MB-231 
Cell Lines
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Figure 7 
 
Figure 7: Endogenous Levels of Acetyl-CoA in the Three Transformed MDA-MB-231 Cell 
Lines. 
Endogenous levels of acetyl-CoA were measured in via HPLC-UV in the three transformed MDA-
MB-231 cell lines. In this figure, Scrambled refers to the MDA-MB-231 cell line that has parental 
levels of NAT1 activity, Down refers to the MDA-MB-231 cell line that has decreased NAT1 
activity, and Up refers to the MDA-MB-231 cell line that has increased NAT1 activity. The bars 
represent results from a single determination in triplicate in nanomoles of acetyl-CoA per one 
million cells ± standard deviation. Bars represent results from a single determination. Statistical 
significance was tested by one-way ANOVA (p=0.0218) followed by a Tukey’s post-hoc test. NS 
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metabolites detected by GC×GC−TOF MS, 52.3% were tentatively identified based on mass 
spectrum and retention index matching. Following student’s t-tests, 8.3% of metabolites detected 
by GC×GC−TOF MS had a p-value ≤ 0.05 and were verified with standards (Table 1). Most of 
these metabolites are amino acids. Two metabolites, L-asparagine and palmitoleic acid, were 
found to be significant across two student’s t-test comparisons. Following a one-way ANOVA, 
29.0% of tentatively identified metabolites had a p ≤ 0.05. After technical validation, only 7.6% of 
metabolites had a one-way ANOVA p ≤ 0.05 and were verified with standards (Table 2). Of the 
metabolites we submitted for technical validation, 52.3% were either misidentified or had no 
standard available for comparison (Table 3).  
After stratification of the metabolites by student’s t-test p-value and fold-change via 
volcano plots, it was observed that L-asparagine and trans-9-octadeconic acid had both a p-value 
≤ 0.05 and a fold-change of at least ± 1.5 between the Scrambled and Down groups (Figure 8); 
between the Scrambled and Up groups, L-threonine, palmitoleic acid, and L-asparagine had both 
a p-value ≤ 0.05 and a fold-change of at least ± 1.5 (Figure 9). From the volcano plot comparing 
the Down and Up groups, L-threonine, palmitoleic acid, and L-ornithine had both a p-value ≤ 0.05 
and a fold-change of at least ± 1.5 (Figure 10). In the volcano plots, only those metabolites that 
had a both a p-value ≤ 0.05 and a fold-change of at least ± 1.5 were labeled. 
Box plots were created for all metabolites that were identified to be significant and had a 
fold change of ± 1.5 between at least 2 of the groups. The metabolites L-leucine, L-aspartic acid, 
and L-valine display the same abundance distribution pattern between the Scrambled, Down, and 
Up groups (Figure 11). The Down group has the lowest abundance, the Scrambled group has a 
mid-level abundance, and the Up group has the highest abundance. The box plot for palmitoleic 
acid shows that the Up group has the lowest abundance while the Scrambled group has the 
highest abundance (Figure 12). Of the seven amino acids that are degraded to acetyl-CoA, only 
leucine, tyrosine, and threonine were verified with standards and showed a significant difference 
in abundance distribution between the three groups (Figure 13). 




Table 1: Metabolites Altered by an Increase or Decrease in NAT1 Activity in Breast Cancer 
Cells  
Metabolites differed significantly between designated groups following student’s t-test, and were 
technically validated. *Down is the reference group, therefore a positive fold change indicates that 
metabolite was higher in the Up group whereas a negative value indicates the metabolite was 
lower in the Up group. #Scrambled is the reference group, therefore a positive fold change 
indicates that metabolite was higher in the Down group whereas a negative value indicates the 
metabolite was lower in the Down group. $Scrambled is the reference group, therefore a positive 
fold change indicates that metabolite was higher in the Up group whereas a negative value 
indicates the metabolite was lower in the Up group. ANOVA q-values were calculated to adjust p-
values for the multiple comparisons we are testing.1tR is the first dimension retention time in 
seconds and 2tR is the second dimension retention time. The CAS number is a unique numerical 














2tR (s) CAS no. 
Up vs  
Down* 
M73 L-threonine 0.0006 0.01 -1.64 1744.578695 0.991514109 72-19-5 
M96 L-aspartic acid 0.0008 0.01 1.44 2243.252686 0.991516707 56-84-8 
M102 palmitoleic acid 0.006 0.04 -1.40 2375.717124 1.043582822 373-49-9 
M66 L-valine <0.0001 0.004 1.36 1640 0.9275 72-18-4 
M69 L-leucine 0.0003 0.008 1.27 1693.142084 0.91843099 61-90-5 
M103 L-ornithine 0.03 0.1 1.73 2376.053736 0.962442604 70-26-8 
Down vs 
Scrambled# 
M106 L-asparagine 0.002 0.02 -1.54 2395.754445 1.064343458 70-47-3 
M113 trans-9-octadecenoic acid 0.01 0.07 -1.90 2573.274268 1.091159053 112-79-8 
Up vs 
Scrambled$ 
M73 L-threonine 0.0009 0.01 -1.62 1744.578695 0.991514109 72-19-5 
M102 palmitoleic acid 0.001 0.02 -1.57 2375.717124 1.043582822 373-49-9 
M106 L-asparagine 0.002 0.02 -1.53 2395.754445 1.064343458 70-47-3 !




Table 2: Metabolites Altered by an Increase and Decrease in NAT1 Activity in Breast 
Cancer Cells 
Ten metabolites were found to differ significantly following a one-way ANOVA and were also 
technically validated with standards. These metabolites were included in subsequent pathway 
analysis. ANOVA q-values were calculated to adjust p-values for the multiple comparisons we are 
testing. 1tR is the first dimension retention time in seconds and 
2tR is the second dimension 
retention time. The CAS number is a unique numerical identifier assigned to chemical compounds 
by the Chemical Abstracts Service (CAS).




2tR (s) CAS no. 
M73 L-threonine 0.0002 0.0009 1744.578695 0.991514109 72-19-5 
M106 L-asparagine 0.002 0.003 2395.754445 1.064343458 70-47-3 
M66 L-valine <0.0001 0.0004 1640 0.9275 72-18-4 
M69 L-leucine <0.0001 0.0004 1693.142084 0.91843099 61-90-5 
M96 L-aspartic acid 0.0008 0.002 2243.252686 0.0.991516707 56-84-8 
M84 L-methionine 0.05 0.03 2034.28795 1.052523863 63-68-3 
M102 palmitoleic acid 0.0001 0.0006 2375.717124 1.0435882822 373-49-9 
M65 beta alanine 0.03 0.02 1626 0.96 107-95-9 
M77 L- proline 0.04 0.03 1789.30765 1.01797484 147-85-3 
M80 glycerol 0.02 0.02 1921.391 0.87520052 56-81-5 !




Status Metabolite Metabolite # 
1tR (s) 
2tR (s) 
V L-glutamine M112 2519.1796 1.0830347 
V L-threonine M73 1744.578695 0.991514109 
V  M86 2097.140471 0.934089146 
V L-asparagine M106 2395.754445 1.064343458 
V 
trans-9-octadecenoic 
acid M113 2573.274268 1.091159053 
V L-valine M66 1640 0.9275 
V L-leucine M69 1693.142084 0.91843099 
V L-aspartic acid M96 2243.252686 0.991516707 
V L-tyrosine M119 2748 1.28 
V L-methionine M84 2034.28795 1.052523863 
V palmitoleic acid M102 2375.717124 1.043582822 
V malic acid M94 2195.57733 0.9831648 
V fumaric acid M78 1827.812518 0.97596729 
V beta-alanine M65 1626 0.96 
V succinic acid M75 1783.060069 1.017216049 
V citric acid M117 2712 1.15 
V L-alanine M57 1483.14905 0.925 
V pidolic acid M83 2016.031208 1.15 
V L-proline M77 1789..30765 1.01797484 
V glycerol M80 1921.391 0.87520052 
V L-ornithine M103 2376.053736 0.962442604 	  
 
*continued on next page 	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Table 3-Continued 	  
U phosphoric acid M87 2109.995458 0.914484667 
U  M88 2069.295505 0.938482329 
U  M93 2098.260648 0.924620606 
U  M99 2313.63 1.039414761 
U  M105 2420.345586 0.795902017 
U  M107 2428.017212 0.791466107 
U  M115 2664.376829 1.095429665 
U  M128 1996.460852 0.989310526 
U  M129 2063.537718 0.943364826 
U 4-bromobutan-1-ol M41 1194 1.005 
U cholesterol M131 3135.889469 1.344001898 
U  M132 3141.608204 1.362317152 
U adenine M108 2415.504303 1.335384303 
U 8-chlorooctan-1-ol M123 1056.667071 0.961182658 
M L-glutamine M116 2696.95982 1.052917405 
M oxalic acid M92 2186.059441 1.025892253 
M  M47 1277.936778 0.848586571 
M malic acid M120 2769.82079 1.149911156 
M  M109 2436.8759 0.93113281 
M beta-alanine M79 1891.871716 1.073551252 
M pidolic acid M90 2242.519873 0.954952753 
M 
 
M100 2353.592825 0.888429472 
M L-lysine M110 2478.422412 0.977623334 
 
Table 3: Tentatively Identified Metabolites Altered by Increased and/or Decreased NAT1 
Activity Subjected to Technical Validation 
V = verified with standards 
U = standard unavailable 
M = retention time does not match standard therefore misidentified





Figure 8: Volcano plot comparing metabolite fold-change and student t-test unadjusted p-
value between the Scrambled and Down transformed cell lines. 
Fold-change of metabolite abundance was calculated and plotted versus unadjusted student’s t-
test p-values to compare the transformed cell lines. In this figure, Scrambled refers to the MDA-
MB-231 cell line that has parental levels of NAT1 activity, Down refers to the MDA-MB-231 cell 
line that has decreased NAT1 activity, and Up refers to the MDA-MB-231 cell line that has 
increased NAT1 activity. Metabolites located at the top left and top right of the plot indicate that 
metabolite has both a substantial fold-change and a significant p-value. The dotted vertical blue 
lines indicate a fold-change of ± 1.5. 
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Figure 9: Volcano plot comparing metabolite fold-change and student t-test unadjusted p-
value between the Scrambled and Up transformed cell lines. 
Fold-change of metabolite abundance was calculated and plotted versus unadjusted student’s t-
test p-values to compare the transformed cell lines. In this figure, Scrambled refers to the MDA-
MB-231 cell line that has parental levels of NAT1 activity, Down refers to the MDA-MB-231 cell 
line that has decreased NAT1 activity, and Up refers to the MDA-MB-231 cell line that has 
increased NAT1 activity. Metabolites located at the top left and top right of the plot indicate that 
metabolite has both a substantial fold-change and a significant p-value. The dotted vertical blue 
lines indicate a fold-change of ± 1.5. 
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Figure 10: Volcano plot comparing metabolite fold-change and student t-test unadjusted p-
value between the Down and Up transformed cell lines. 
Fold-change of metabolite abundance was calculated and plotted versus unadjusted student’s t-
test p-values to compare the transformed cell lines. In this figure, Scrambled refers to the MDA-
MB-231 cell line that has parental levels of NAT1 activity, Down refers to the MDA-MB-231 cell 
line that has decreased NAT1 activity, and Up refers to the MDA-MB-231 cell line that has 
increased NAT1 activity. Metabolites located at the top left and top right of the plot indicate that 
metabolite has both a substantial fold-change and a significant p-value. The dotted vertical blue 
lines indicate a fold-change of ± 1.5. 
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Figure 11 
   
 
 
Figure 11: Box Plots Comparing the Abundance of Specific Metabolites Between the 
Transformed Cell Lines. 
Box plots showing the abundance distribution of the metabolites L-leucine, L-aspartic acid, and L-
valine in the three groups In this figure, Scrambled refers to the MDA-MB-231 cell line that has 
parental levels of NAT1 activity, Down refers to the MDA-MB-231 cell line that has decreased 
NAT1 activity, and Up refers to the MDA-MB-231 cell line that has increased NAT1 activity. 
Abundances were median scaled for each metabolite. The solid black dots represent the mean 


























































Figure 12: Box Plot Comparing the Abundance of the Metabolite Palmitoleic Acid Between 
the Transformed Cell Lines. 
Box plot showing the abundance distribution of the metabolite palmitoleic acid in the three 
groups. In this figure, Scrambled refers to the MDA-MB-231 cell line that has parental levels of 
NAT1 activity, Down refers to the MDA-MB-231 cell line that has decreased NAT1 activity, and 
Up refers to the MDA-MB-231 cell line that has increased NAT1 activity. The solid black dots 
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Figure 13 
 
Figure 13: Box Plot of Amino Acids that are Broken Down to Form Acetyl-CoA.  
Box plot showing the abundance distribution of amino acids that are degraded to form acetyl-
CoA. In this figure, Scrambled refers to the MDA-MB-231 cell line that has parental levels of 
NAT1 activity, Down refers to the MDA-MB-231 cell line that has decreased NAT1 activity, and 
Up refers to the MDA-MB-231 cell line that has increased NAT1 activity. The solid black dots 
represent the mean and the open dots represent outliers. Abundances were median scaled for 
each metabolite. L-leucine and L-tyrosine exhibit the same distribution pattern with metabolite 
levels increased in the Up group when compared to the Scrambled and Down groups. The two L-
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MULTIVARIATE/MULTIVARIABLE ANALYSIS 
The goal of using multivariate/multivariable analyses methods is to identify groups of 
metabolites that, together, are driving between group variation versus within-group variation. 
Principal Component Analysis (PCA) was the first multivariate approach used. Principal 
component 1 (PC1) of PCA separated the Down group from the Scrambled and Up groups but 
two component PCA did not discriminate between the Scrambled and Up groups (Figure 14). 
Therefore, Partial Least Squares- Discriminate Analysis (PLS-DA) methods were used in an 
attempt to achieve separation between all three groups with a single principle component. Two 
component PLS-DA led to complete group separation but within group variation and between 
group variation were both contributing to each component (Figure 15). We then proceeded to the 
multivariate analysis method, Orthogonal Partial Least Squares- Discriminate Analysis (OPLS-
DA). Two component OPLS-DA showed complete group separation with component 1 explaining 
group predictive variation and component 2 explaining variation uncorrelated with group 
membership (Figure 16). Since component 1 of the OPLS-DA showed complete group 
separation, the loadings of that component were plotted to show which metabolites were 
contributing the most to the separation (Figure 17). The loadings of component 1 from OPLS-DA 
show that L-threonine, L-glutamine, and oxalic acid are driving the separation between the groups 
and are higher in the Down group and conversely lower in the Up group. The loadings of 
component 1 from OPLS-DA also show L-valine, L-leucine, and L-aspartic acid are driving the 
separation between the groups but are higher in the Up group and conversely lower in the Down 
group.





Figure 14: Principal Component Analysis (PCA) Scores Plot 
Two component PCA explains 40% of the total variance. In this figure, S (in black) refers to the 
MDA-MB-231 cell line that has parental levels of NAT1 activity, D (in blue) refers to the MDA-MB-
231 cell line that has decreased NAT1 activity, and U (in red) refers to the MDA-MB-231 cell line 
that has increased NAT1 activity. The number following each letter indicates the individual 
sample number. Each component on the axes represents a linear combination of all metabolites.  
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Figure 15: Partial Least Squares-Discriminate Analysis (PLS-DA) Scores Plot 
Two component PLS-DA showed separation between the groups. In this figure, S (in black) refers 
to the MDA-MB-231 cell line that has parental levels of NAT1 activity, D (in blue) refers to the 
MDA-MB-231 cell line that has decreased NAT1 activity, and U (in red) refers to the MDA-MB-
231 cell line that has increased NAT1 activity. The number following each letter indicates the 
individual sample number. Each component represents a linear combination of all metabolites.  
 







































Figure 16: Orthogonal Partial Least Squares Discriminate Analysis (OPLS-DA) Scores Plot 
OPLS-DA achieved complete separation between all groups. In this figure, S (in black) refers to 
the MDA-MB-231 cell line that has parental levels of NAT1 activity, D (in blue) refers to the MDA-
MB-231 cell line that has decreased NAT1 activity, and U (in red) refers to the MDA-MB-231 cell 
line that has increased NAT1 activity. The number following each letter indicates the individual 
sample number. Each component represents a linear combination of all metabolites. 
 
 






































Figure 17: Jack-knife loadings plot for component 1 of the OPLS-DA.  
The metabolites at the extremes of the plot are the largest contributors to the separation of the 




















































































































































































































































































































































































































































































	   39 
DISCUSSION
 
 The purpose of this study was to identify metabolic changes induced by varying levels of 
human NAT1 in MDA-MB-231 breast cancer cells. It is our hypothesis that changing the level of 
NAT1 activity will lead to alterations in the levels of acetyl-coenzyme A (acetyl-CoA). Increased 
NAT1 activity would lead to increased hydrolysis of acetyl-CoA therefore less free acetyl-CoA 
would be available. Conversely, decreased NAT1 activity would lead to decreased hydrolysis of 
acetyl-CoA therefore more free acetyl-CoA would be available. It is our hypothesis that due to 
fluctuations in the amount of free acetyl-CoA available, cellular pathways will be altered. Acetyl-
CoA is a central mediator of many cellular pathways (Figure 18). 
Many of the breast cancer cell lines used in research have innately different levels of 
human NAT1 activity. Wakefield et al. have reported that the NAT1 activity in breast cancer cell 
lines range from 0.1 ± 0.02 nmol PABA acetylated/min/mg protein in Cal51 cells to 202.2 ± 28 
nmol PABA acetylated/min/mg protein in ZR-75-1 cells [34]. With our transformed MDA-MB-231 
cell lines, not only do they express varying levels of NAT1 activity, ranging from 11.6 ± 0.6 nmol 
PABA acetylated/min/mg protein in the Down cell line to 233.9 ± 2.2 nmol PABA 
acetylated/min/mg protein in the Up cell line, but they also have the same genetic background. 
This removes any confounding factors due to genetic differences that would arise if we performed 
this same study using the cell lines that innately have different NAT1 activity. Ideally, we wanted 
the Down cell line to have little to no NAT1 activity but when utilizing shRNA that targets NAT1 
the most we have been able to knock-down NAT1 activity has been by 50% when compared to 
the parent cell line. We have recently constructed two MDA-MB-231 complete NAT1 knockout 
cell lines in our lab using the CRISPR® system that will be used in further studies (see future 
directions for more details).  
 





Figure 18- Acetyl-CoA is a Central Molecule Involved in a Plethora of Reactions. 
Acetyl-CoA is a central molecule involved in many pathways including fatty acid synthesis and 
degradation, the citric acid cycle (TCA Cycle), and ketone body and isoprenoid synthesis. 
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In our characterization of the transformed cell lines, we found that relative to the 
Scrambled cell line, the Down cell line expressed 50% of the NAT1 mRNA and the Up cell line 
expressed 31 times the NAT1 mRNA. We also found that the Down cell line had 61% of the 
NAT1 activity and the Up cell line had 1240% the NAT1 activity of the Scrambled cell line. The 
difference in NAT1 mRNA expression between the Scrambled and Down groups was not 
statistically significant by a Tukey’s post-hoc test but, the difference in NAT1 activity between the 
Scrambled and Down groups was statistically significant by a Tukey’s post-hoc test. We postulate 
that this is due to the difference in standard error of the mean (SEM) between the two 
measurements. The SEM is much larger for the NAT1 mRNA measurement in the Scrambled 
group when compared to the SEM for the NAT1 activity measurement in the same group. 
When we began this study it was our hypothesis that changing the level of NAT1 activity 
would change the level of free acetyl-CoA available and this change in acetyl-CoA levels would 
thus induce alterations in cellular pathways. In this study we observed that the levels of 
endogenous acetyl-CoA are decreased in the transformed MDA-MB-231 cell line expressing 
increased NAT1 acetylation activity when compared to the transformed MDA-MB-231 cell line 
expressing parental levels of NAT1 acetylation activity. This is the first study to compare 
endogenous levels of acetyl-CoA in samples that express varying levels of NAT1. This finding, 
combined with our original hypothesis, led us to begin the pathway analysis portion of this study 
by first following pathways that involved acetyl-CoA and identifying where the metabolites that 
were classified as significant and were verified with standards were located in those pathways. 
We then applied our hypothesis to see if the change in abundance of metabolite were biologically 
plausible. In the metabolomics portion of this study, the abundance of palmitoleic acid was shown 
to be decreased in the Up group when compared to the Scrambled group with a student’s t-test p-
value < 0.005 and a fold change of 1.57. Our refined hypothesis is that in the Up group, acetyl-
CoA hydrolysis by NAT1 is increased when compared to the Scrambled group, leaving less free 
acetyl-CoA available for other reactions.  
We expected to see an increase in the flux of acetyl-CoA through the fatty acid synthesis 
pathway in the cell line that had increased NAT1 activity since cancer cells require increased 
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amounts of cellular components and energy due to their rapidly dividing nature and 
overexpression of NAT1 in cell lines has been shown to increase cell growth and invasion. The 
fatty acid synthesis pathway (Figure 19) begins with the synthesis of malonyl-CoA by acetyl-CoA 
carboxylase (ACC) from acetyl-CoA and bicarbonate. Acetyl-CoA carboxylase (ACC) is a biotin-
dependent enzyme that catalyzes the irreversible carboxylation of acetyl-CoA to 
produce malonyl-CoA through its two catalytic activities. In the next step of fatty acid synthesis, 
malonyl-CoA and acetyl-CoA are combined by fatty acid synthase I (FAS1) to form palmitate 
(16:0). Palmitate is a branch point in the fatty acid synthesis pathway. Either stearate (18:0) or 
palmitoleic acid (16:1 (Δ9)) can be synthesized from palmitate. Palmitoleic acid is synthesized 
from palmitate by fatty acyl-CoA desaturase. Palmitate negatively feeds back on acetyl-CoA 
carboxylase (ACC) thus preventing further palmitate generation. In this study we saw a decrease 
in the abundance of palmitoleic acid (16:1 (Δ9)) when NAT1 activity was increased. We now 
propose that the abundance of palmitoleic acid is decreased in the cell line that has increased 
NAT1 activity because there is less free acetyl-CoA available therefore palmitate is selectively 
shunted to the other branch of the fatty acid synthesis pathway, which synthesizes stearate. To 
test this we need to measure the levels of stearate to see how they compare between the three 
cell lines. 
 There are seven amino acids that are degraded to acetyl-CoA; these amino acids are 1. 
tryptophan, 2. lysine, 3. phenylalanine, 4. tyrosine, 5. leucine, 6. isoleucine, and 7. threonine. If 
our hypothesis that different levels of human NAT1 in the MDA-MB-231 cells lead to altered 
levels of acetyl-CoA and these altered levels of acetyl-CoA lead to alterations in cellular pathways 
is correct, it is plausible that there could be increased or decreased degradation of one or more of 
these seven amino acids to compensate for the altered levels of acetyl-CoA. In our data, leucine, 
tyrosine, and threonine were verified with standards and showed a significant difference in 
abundance distribution between the three groups. Of those three amino acids, leucine and 
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Figure 19 
 
Figure 19: Abbreviated Fatty Acid Synthesis Pathway.  
This pathway shows the utilization of Acetyl-CoA in the fatty acid synthesis pathway. Palmitoleic 
acid is synthesized from palmitate by the enzyme fatty acyl-CoA desaturase. Palmitate can also 
be elongated to form stearate which can then be further elongated to form longer saturated fatty 
acids. The numbers in parentheses next to the names of the fatty acids are lipid numbers which 
have the form C:D, where C is the number of carbon atoms and D is the number of double bonds 
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tyrosine had the same relative abundance distribution suggesting there may be a shared 
mechanism by which these metabolites are being regulated. 
As with any study involving a high number of comparisons, there is the chance that some 
of the observed changes in abundance of metabolites are due to random chance. We have 
decreased the likelihood of pursuing metabolites where this may be the case by choosing 
metabolites for further investigation that are involved in pathways that also involve acetyl-CoA. By 
doing this we can develop a rationale for why the abundance of that metabolite would be changed 
between cells expressing varying levels of NAT1 activity. 
 In the metabolomics data there were several misidentified metabolites that were both 
statistically significant and had a fold change of 1.5 or greater. One such metabolite, M116, with a 
one-way ANOVA p < 0.0001 was initially identified as L-glutamine but was later shown to be 
misidentified when compared to the L-glutamine standard. Unfortunately, there is currently not a 
way for us to retroactively identify these metabolites; we can only see that they are misidentified. 
As a result we may be missing important metabolites that could provide a key link between 
varying levels of NAT1 and altered cellular metabolism. As the field of metabolomics progresses, 
libraries containing spectral data of metabolites will become more complete and lead to a larger 
number of identified metabolites in future studies. 
 If our proposed hypothesis holds true, we would expect the abundance distribution of any 
metabolite that is changed, as a result of the level of NAT1 activity, to show the Scrambled group 
in the middle with the Up and Down groups above and below or below and above. This is not 
necessarily true though as there may be compensatory mechanisms that are regulating the 
amount of acetyl-CoA. Also, there may be a threshold in the amount of acetyl-CoA that must be 
altered in order for a change in metabolite abundance to be observed. 
 Another concern in metabolomics studies is the threshold of detection. Some metabolites 
are present in cells at levels that are too small to be accurately measured or even detected but 
that does not mean the abundance of those metabolites are not changing. A small change in 
these metabolites could have a greater impact than metabolites that are present in the cells at 
higher abundances and can be easily measured. 
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SUMMARY AND CONCLUSIONS
 
STRENGTHS OF THIS WORK 
 The construction of three stably transfected cell lines provided stable breast cancer cell 
line models whose only genetic difference is the level of human NAT1 activity. Before the 
construction of these cell lines, comparison between cell lines that expressed different levels of 
NAT1 activity was limited to evaluating cell lines whose endogenous NAT1 activity varied. In the 
cell lines that endogenously express varying levels of NAT1 activity there are also other 
differences that have to be taken into account, including mutation differences such as estrogen 
receptor (ER), progesterone receptor (PR), and Her2/neu status, among many others, when 
comparing the results of those studies. With these new cell lines, the effect NAT1 activity has on 
cancer progression can be more thoroughly evaluated with less confounding factors. We have 
utilized this advantageous new resource to show for the first time that endogenous acetyl-CoA 
levels vary between samples whose only difference is the level of NAT1 activity. Acetyl-CoA is a 
central molecule involved in a plethora of reactions, including fatty acid synthesis and the TCA 
cycle. 
 Also, this study is the first to investigate the effect of varying human NAT1 activity on the 
metabolome of a breast cancer cell line. Metabolomics has developed into an extremely 
beneficial and information-rich area of research as of late, but has been under-utilized in regards 
to research on the NAT isozymes. Analysis of metabolomics data can help reveal what pathways 
are altered as a result of varying levels of NAT1 activity thus providing insights into the role NAT1 
has in breast cancer disease and progression. A greater understanding of the role NAT1 has in 
breast cancer could lead to better detection and treatment methods. 
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CAVEATS AND WEAKNESSES 
 MDA-MB-231 triple-negative breast cancer cells were chosen for manipulation of NAT1 
activity and subsequent analyses in this study. MDA-MB-231 cells are known to have mutations 
in 5 genes, including BRAF, CDKN2A, KRAS, NF2, and TP53. These mutations may complicate 
evaluation of the effect NAT1 has on cancer risk. Since these cells are already cancerous in 
nature, evaluating the risk NAT1 levels play in cancer risk is muddled at best. A fundamental 
complementation to this study would include the manipulation of human NAT1 activity in other 
breast cancer cell lines and cells from normal breast tissue. 
 Comparison of NAT1 activity between the three transformed cell lines revealed that while 
the Up cell line has approximately thirteen times the NAT1 activity of the Scrambled cell line, the 
NAT1 activity in the Down cell line is only decreased by approximately 50%. The difference in 
NAT1 activity between the Scrambled and Up cell lines is so drastic that it may overshadow 
differences between the Scrambled and Down cell lines. Comparison of endogenous acetyl-CoA 
levels also only showed a statistically significant difference between the Scrambled and Up cell 
lines. We were hoping to completely knockdown the NAT1 activity in our down cell line however 
an approximate 50% decrease in activity was the most that could be achieved when utilizing our 
methods. Additional methods that knockout rather than knockdown the NAT1 gene have helped 
us achieve a cell line with no NAT1 activity, that will be used in future studies. 
 An additional caveat to this study is the use of cell lines as opposed to patient derived 
tumor samples. Tumors are not made up of a single cell-type but multiple cell types that each 
play a unique role while cell lines are a homogenous collection of cells. Also, these multiple cell 
types found in tumors exist in a tumor micro-environment (TME) that plays a big role in cancer 
progression. It has been shown that cancer cells secrete paracrine growth factors that recruit 
stromal cells then the stromal cells secrete cytokines which accelerate the aggressiveness of 
cancer cells [54]. It has also been shown that the TME allows complex metabolic interactions 
between the tumor and surrounding cell types. Unfortunately, since we are using cell lines as our 
samples in this study, we may be missing out on important metabolic changes due to the TME.   
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 The samples prepared for metabolomics were not incubated with any NAT1 substrates. 
Humans are exposed to NAT1 substrates frequently, therefore the condition under which the cells 
were collected may not represent the most biologically relevant conditions. However, this does 
allow us to investigate a possible endogenous role for NAT1. Fellow researchers who work with 
NAT1 have postulated that NAT1 has an undiscovered endogenous role given that it is distributed 
throughout most tissues of the body and found in almost every species. 
 In cell lines, metabolites can be found both within the cells themselves and also within the 
medium the cells have been cultured in since some metabolites are excreted from the cells. In 
this study we chose to collect only the cell pellets for metabolomics sample preparation and 
discarded the media they were cultured in. The metabolites excreted into the culture medium may 
also provide valuable insights into cellular pathway alternations that were missed by analyzing 
metabolites from cell pellets only. We may have missed important differences in the metabolites 
that were excreted into the media.  
 In this study we only extracted and examined polar metabolites from the cell pellet 
samples. Examples of polar metabolites include sugars and most amino acids while examples of 
non-polar metabolites include membrane lipids and long-chain fatty acids. We expect to observe 
a greater difference in non-polar metabolites than polar metabolites since acetyl-CoA is a central 
mediator of fatty acid synthesis and we hypothesize that varying levels of NAT1 activity influence 
cellular metabolism through regulation of acetyl-CoA. By increasing the number of platforms used 
to detect metabolites in our samples, a wider range of metabolites can be detected thus giving a 
more complete picture of any metabolic flux or alterations that are occurring. 
FUTURE DIRECTIONS 
 In the future we will be performing further metabolomics studies that cover a wider range 
of metabolites, including both polar and non-polar metabolites. This will be accomplished by 
applying a comprehensive metabolomics approach that will involve measurement of metabolites 
across six different platforms including 1. GCXGC-TOF MS, 2. LC-MS, 3. UHPLC-MS/MS (+ESI), 
4. UHPLC-MS/MS (-ESI), 5. UHPLC-MS/MS (HILIC), and 6. GC-MS (+EI). Once metabolic 
differences between the cell lines are identified, we will then use biochemical approaches such as 
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high pressure liquid chromatography-ultraviolet detection (HPLC-UV) and spectrophotometric 
enzyme-coupled assays to verify the metabolites’ identities and then hypothesize a mechanism 
by which NAT1 contributed to these differences. The biochemical approach chosen will depend 
on the metabolite. 
Our lab has recently completed the creation of heterozygous and homozygous NAT1 
knockout MDA-MB-231 cells using the CRISPR™ system. The CRISPR™ system utilizes guide 
RNA’s (gRNA’s) that specifically target one’s gene of interest, which in our case is human NAT1, 
and induce DNA damage in that gene. The DNA damage and subsequent repair mechanisms 
lead to mutations in the gene which result in the knockout of the gene. These two additional cell 
lines with altered NAT1 activity are an incredibly valuable addition to the three transformed cell 
lines used for this project. Further metabolomics studies will include two CRISPR™ homozygous 
NAT1 knockout MDA-MB-231 cell lines that were constructed using two different gRNA’s. By 
using MDA-MB-231 NAT1 knockouts that were generated using two different gRNA’s we will be 
able to differentiate changes in metabolites that are due to NAT1 levels as opposed to possible 
off target effects of the gRNA’s. We are also working on creating NAT1 knockout MCF-7 and ZR-
75-1 cells using the CRISPR™ system. 
Also, our lab is currently in the process of using the FLP-In System™ to construct MCF-7, 
MCF-10a, and ZR-75-1 transfected breast cancer cell lines that stably overexpress and 
underexpress human NAT1. By repeating our study with these additional cell lines, we will be 
able to show that the observed changes from our initial study are repeatable and not merely a 
consequence of using MDA-MB-231 cells as the parental cell line.  
	   49 
REFERENCES
 
1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA Cancer J Clin, 2015. 
65(1): p. 5-29. 
2. DeSantis, C., et al., Breast cancer incidence rates in U.S. women are no longer declining. 
Cancer Epidemiol Biomarkers Prev, 2011. 20(5): p. 733-9. 
3. National Cancer Institute. PDQ® Breast Cancer Treatment. 10/24/2014 [cited 2014 
11/18]; Available from: http://cancer.gov/cancertopics/pdq/treatment/breast/Patient. 
4. Sorlie, T., et al., Gene expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications. Proc Natl Acad Sci U S A, 2001. 98(19): p. 10869-
74. 
5. Munirah, M.A., et al., Identification of different subtypes of breast cancer using tissue 
microarray. Rom J Morphol Embryol, 2011. 52(2): p. 669-77. 
6. Hein, D.W., et al., Molecular genetics and epidemiology of the NAT1 and NAT2 
acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev, 2000. 9(1): p. 29-42. 
7. Hein, D.W., Molecular genetics and function of NAT1 and NAT2: role in aromatic amine 
metabolism and carcinogenesis. Mutat Res, 2002. 506-507: p. 65-77. 
8. Matas, N., et al., Mapping AAC1, AAC2 and AACP, the genes for arylamine N-
acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a 
region frequently deleted in tumours. Cytogenet Cell Genet, 1997. 77(3-4): p. 290-5. 
9. Blum, M., et al., Human arylamine N-acetyltransferase genes: isolation, chromosomal 
localization, and functional expression. DNA Cell Biol, 1990. 9(3): p. 193-203. 
10. Sim, E., et al., Arylamine N-acetyltransferase. Biochem Soc Trans, 1992. 20(2): p. 304-9. 
11. Liu, L., et al., Arylamine N-acetyltransferases: characterization of the substrate 
specificities and molecular interactions of environmental arylamines with human NAT1 
and NAT2. Chem Res Toxicol, 2007. 20(9): p. 1300-8. 
12. Minchin, R.F., Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by 
recombinant human arylamine N-acetyltransferase and U937 cells. Biochem J, 1995. 307 
( Pt 1): p. 1-3. 
13. Weber, W.W. and D.W. Hein, N-acetylation pharmacogenetics. Pharmacol Rev, 1985. 
37(1): p. 25-79. 
14. DeBruin, L.S., J.B. Pawliszyn, and P.D. Josephy, Detection of monocyclic aromatic 
amines, possible mammary carcinogens, in human milk. Chem Res Toxicol, 1999. 12(1): 
p. 78-82. 
15. Possanzini, M. and V. Dipalo, Improved Hplc Determination of Aliphatic-Amines in Air by 
Diffusion and Derivatization Techniques. Chromatographia, 1990. 29(3-4): p. 151-154. 
16. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans., World Health 
Organization., and International Agency for Research on Cancer., Some aromatic 
amines, organic dyes, and related exposures. IARC monographs on the evaluation of 
carcinogenic risks to humans,. 2010, Lyon: IARC Press. viii, 692 p. 
17. Laurieri, N., et al., From arylamine N-acetyltransferase to folate-dependent acetyl CoA 
hydrolase: impact of folic acid on the activity of (HUMAN)NAT1 and its homologue 
(MOUSE)NAT2. PLoS One, 2014. 9(5): p. e96370. 
18. Clark, D.W., Genetically determined variability in acetylation and oxidation. Therapeutic 
implications. Drugs, 1985. 29(4): p. 342-75. 
19. Eichelbaum, M., H.K. Kroemer, and G. Mikus, Genetically-Determined Differences in 
Drug-Metabolism as a Risk Factor in Drug Toxicity. Toxicology Letters, 1992. 64-5: p. 
115-122. 
	   50 
20. Ohno, M., et al., Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid 
and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis, 2000. 4(3): p. 256-61. 
21. Butcher, N.J. and R.F. Minchin, Arylamine N-acetyltransferase 1: a novel drug target in 
cancer development. Pharmacol Rev, 2012. 64(1): p. 147-65. 
22. Casey, T., et al., Molecular signatures suggest a major role for stromal cells in 
development of invasive breast cancer. Breast Cancer Res Treat, 2009. 114(1): p. 47-62. 
23. Chin, K., et al., Genomic and transcriptional aberrations linked to breast cancer 
pathophysiologies. Cancer Cell, 2006. 10(6): p. 529-41. 
24. Yuan, Y., et al., A sparse regulatory network of copy-number driven gene expression 
reveals putative breast cancer oncogenes. IEEE/ACM Trans Comput Biol Bioinform, 
2012. 9(4): p. 947-54. 
25. Adam, P.J., et al., Arylamine N-acetyltransferase-1 is highly expressed in breast cancers 
and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res, 
2003. 1(11): p. 826-35. 
26. Smid, M., et al., Genes associated with breast cancer metastatic to bone. J Clin Oncol, 
2006. 24(15): p. 2261-7. 
27. Vatsis, K.P. and W.W. Weber, Structural heterogeneity of Caucasian N-acetyltransferase 
at the NAT1 gene locus. Arch Biochem Biophys, 1993. 301(1): p. 71-6. 
28. Weber, W.W. and K.P. Vatsis, Individual variability in p-aminobenzoic acid N-acetylation 
by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics, 1993. 
3(4): p. 209-12. 
29. Grant, D.M., et al., Human acetyltransferase polymorphisms. Mutat Res, 1997. 376(1-2): 
p. 61-70. 
30. N-acetyltransferase Gene Nomenclature Committee. Human NAT1 Alleles (Haplotypes). 
1-11-13 [cited 2015 Jan 30]; Available from: http://nat.mbg.duth.gr/Human NAT1 
alleles_2013.htm. 
31. Badawi, A.F., et al., Role of aromatic amine acetyltransferases, NAT1 and NAT2, in 
carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res, 1995. 
55(22): p. 5230-7. 
32. Bell, D.A., et al., Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) 
increases risk of colorectal cancer. Cancer Res, 1995. 55(16): p. 3537-42. 
33. de Leon, J.H., K.P. Vatsis, and W.W. Weber, Characterization of naturally occurring and 
recombinant human N-acetyltransferase variants encoded by NAT1. Mol Pharmacol, 
2000. 58(2): p. 288-99. 
34. Wakefield, L., et al., Arylamine N-acetyltransferase 1 expression in breast cancer cell 
lines: a potential marker in estrogen receptor-positive tumors. Genes Chromosomes 
Cancer, 2008. 47(2): p. 118-26. 
35. Chatterjee, Malay, and Khosrow Kashfi. "Human Arylamine N-acetyltransferase 1: From 
Drug Metabolism to Drug Target." Cell Signaling & Molecular Targets in Cancer. New 
York: Springer, 2012. 30-31.  
36. Dupret, J.M., et al., Inactivation of human arylamine N-acetyltransferase 1 by hydrogen 
peroxide and peroxynitrite. Methods Enzymol, 2005. 400: p. 215-29. 
37. Rodrigues-Lima, F., J. Dairou, and J.M. Dupret, Effect of environmental substances on 
the activity of arylamine N-acetyltransferases. Curr Drug Metab, 2008. 9(6): p. 505-9. 
38. Buranrat, B., et al., Inflammatory cytokines suppress arylamine N-acetyltransferase 1 in 
cholangiocarcinoma cells. World J Gastroenterol, 2007. 13(46): p. 6219-25. 
39. Russell, A.J., et al., Selective small molecule inhibitors of the potential breast cancer 
marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse 
arylamine N-acetyltransferase 2. Bioorg Med Chem, 2009. 17(2): p. 905-18. 
40. Tiang, J.M., N.J. Butcher, and R.F. Minchin, Small molecule inhibition of arylamine N-
acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast 
cancer cells. Biochem Biophys Res Commun, 2010. 393(1): p. 95-100. 
41. Leggett, C., Role of Human Arylamine N-Acetyltransferase in Carcinogen Metabolism 
and Human Breast Cancer Progression. Diss. University of Louisville, 2012. 
	   51 
42. Ragunathan, N., et al., Cadmium alters the biotransformation of carcinogenic aromatic 
amines by arylamine N-acetyltransferase xenobiotic-metabolizing enzymes: molecular, 
cellular, and in vivo studies. Environ Health Perspect, 2010. 118(12): p. 1685-91. 
43. Sanfins, E., et al., Carbon black nanoparticles impair acetylation of aromatic amine 
carcinogens through inactivation of arylamine N-acetyltransferase enzymes. ACS Nano, 
2011. 5(6): p. 4504-11. 
44. Paterson, S., et al., Histone deacetylase inhibitors increase human arylamine N-
acetyltransferase-1 expression in human tumor cells. Drug Metab Dispos, 2011. 39(1): p. 
77-82. 
45. Perou, C.M., et al., Distinctive gene expression patterns in human mammary epithelial 
cells and breast cancers. Proc Natl Acad Sci U S A, 1999. 96(16): p. 9212-7. 
46. Zhao, H., et al., Different gene expression patterns in invasive lobular and ductal 
carcinomas of the breast. Mol Biol Cell, 2004. 15(6): p. 2523-36. 
47. Wang, Y., et al., Gene-expression profiles to predict distant metastasis of lymph-node-
negative primary breast cancer. Lancet, 2005. 365(9460): p. 671-9. 
48. Endo, Y., et al., miR-1290 and its potential targets are associated with characteristics of 
estrogen receptor alpha-positive breast cancer. Endocr Relat Cancer, 2013. 20(1): p. 91-
102. 
49. Endo, Y., et al., Immunohistochemical determination of the miR-1290 target arylamine N-
acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer. BMC Cancer, 
2014. 14: p. 990. 
50. Bieche, I., et al., Relationship between intratumoral expression of genes coding for 
xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen 
receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res, 2004. 
6(3): p. R252-63. 
51. Tiang, J.M., et al., RNAi-mediated knock-down of arylamine N-acetyltransferase-1 
expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS 
One, 2011. 6(2): p. e17031. 
52. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 
144(5): p. 646-74. 
53. Millner, L.M., et al., NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 
mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-
aminobiphenyl. Mol Carcinog, 2012. 51(8): p. 636-46. 
54. Romero, I.L., et al., Molecular pathways: trafficking of metabolic resources in the tumor 
microenvironment. Clin Cancer Res, 2015. 21(4): p. 680-6. 
	   52 
ABBREVIATIONS
 
Acetyl-CoA  acetyl-coenzyme a 
ANOVA   analysis of variance 
BRCA1   breast cancer 1, early onset 
BRCA2   breast cancer 2, early onset 
cDNA   complementary deoxyribonucleic acid 
FRT   flippase recognition target 
GC×GC−TOF MS  two dimensional gas chromatogrpahy time-of-flight mass spectrometry 
gRNA   guide ribonucleic acid 
HPLC   high pressure liquid chromatography 
mRNA   messenger ribonucleic acid 
MTBSTFA   N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide 
OPLS-DA  orthogonal partial least squares- discriminant analysis 
NAT1   arylamine N-acetyltransferase 1 
NAT2   arylamine N-acetyltransferase 2 
PABA   para-aminobenzoic acid 
PCA   principle component analysis 
PLS-DA  partial least squares- discriminant analysis 
qRT-PCR  quantitative real time polymerase chain reaction 
SEM   standard error of the mean 
shRNA   short hairpin ribonucleic acid 
TME   tumor microenvironment 
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